Key Insights

Highlights

Success Rate

83% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

12.5%

2 terminated out of 16 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed with results

Key Signals

4 with results83% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (2)
P 1 (7)
P 2 (5)
P 3 (1)

Trial Status

Completed10
Terminated2
Withdrawn2
Recruiting1
Active Not Recruiting1

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT01891318Phase 1RecruitingPrimary

Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

NCT01843413Phase 1Active Not RecruitingPrimary

Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases

NCT01703507Phase 1Completed

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

NCT02145910Phase 1Withdrawn

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

NCT01706432Completed

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

NCT02107755Phase 2Completed

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

NCT02312622Phase 2Completed

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

NCT00033254Phase 3CompletedPrimary

Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases

NCT02277561Not ApplicableWithdrawnPrimary

Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery

NCT02269111Not ApplicableTerminatedPrimary

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

NCT01234740Phase 1Completed

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

NCT01276210Phase 1CompletedPrimary

Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

NCT00992602Phase 2Completed

Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

NCT00098605Phase 2Completed

Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases

NCT00937482Phase 1Terminated

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00072163Phase 2Completed

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

Showing all 16 trials

Research Network

Activity Timeline